UNIVERSITY OF EDINBURGH

Ananda Developments announces two Phase III trials for refractory epilepsy using its MRX2 (CBD) and MRX2T (CBD + THC) compounds, co-funded by NIHR and NHS, aiming to evaluate safety and efficacy in children and adults. These trials, conducted by UCL and GOSH, involve up to 500 patients and are designed to support regulatory approval. Ananda's CEO emphasizes focusing on meeting regulatory requirements to move research forward.

Preschoolers prone to tantrums have a higher risk of ADHD by age 7, with poorer emotion regulation linked to more ADHD symptoms, according to a study involving 19,000 U.K. children born between 2000-2002.

ChapsVision acquires Sinequa; Answer ALS and Cedars-Sinai release largest ALS iPSC and bio data repository; Healx to use Sanofi compound with AI platform Healnet; Scale Biosciences and BioLegend launch TotalSeq Phenocyte single-cell protein profiling solution; GeneDx introduces GeneDx Discover data visualization tool; Model N integrates generative AI and data capabilities; NCSA launches DeltaAI; Sapio Sciences and Waters Corporation enhance lab productivity; CapeStart debuts MadeAi platform; Trogenix unveils cancer treatment platform; Exagen submits new SLE and RA biomarkers for approval; C-Path launches GEM-PD initiative; BioNTech acquires Biotheus; Stand Up To Cancer collaborates with Johnson & Johnson on AL amyloidosis treatment; Nxera and Antiverse partner for GPCR antibody design; CCRM Nordic, Sahlgrenska Academy, and Sahlgrenska University Hospital form ATMP partnership; BC Platforms, Modirum Platforms, and VEIL.AI deploy software for EHDS2 framework; Evogene collaborates with Google Cloud on generative AI for small molecule design; Parse Biosciences launches GigaLab for single cell sequencing; Gingko Bioworks introduces Antibody Developability product.

Resolution Therapeutics receives AEMPS approval to expand Phase 1/2 EMERALD study of RTX001, an engineered macrophage therapy, into Spain, following U.K. MHRA approval and ongoing recruitment. The study aims to assess safety and efficacy in end-stage liver disease patients, with recruitment expected in Spain in Q2 2025.

Trogenix, a spinout from the University of Edinburgh, unveils its precision viral immunotherapy platform for aggressive cancers, attracting investment from IQ Capital, Cancer Research Horizons, and others. The platform uses Synthetic Super-Enhancers to target cancer cells selectively, with preclinical success in glioblastoma and plans for Phase 1/2 trials in 2025.

Trogenix, a spinout from the University of Edinburgh, unveils its precision viral immunotherapy platform, Odysseus, targeting aggressive cancers. The company, backed by 4BIO Capital and other investors, aims to transform cancer treatment from chronic management to potentially curative one-time treatments. Trogenix's Synthetic Super-Enhancer technology enables selective targeting of cancer cells, activating the immune system while leaving healthy cells untouched. The lead programme targets glioblastoma, with Phase 1/2 trials planned for 2025.

NICE declined to recommend lecanemab and donanemab, new monoclonal antibody treatments for Alzheimer’s disease, in draft guidelines due to high costs and concerning side effects, despite MHRA licensing them for early-stage AD patients with no or one copy of the ApoE4 gene.

University of Glasgow researchers developed a new malaria drug, targeting PfCLK3 protein, potentially more effective and resistant to resistance, with a single-dose possibility.